Clinical Trials

NCT01543763 2025-03-21

Pazopanib in Combination With PCI-24781 in Patients With Metastatic Solid Tumors

90 enrolled

Neoplasm Metastasis, Sarcoma, Disease Progression

NCT02207309 2024-08-09

Hemangiosarcoma, Sarcoma

NCT02357810 2022-06-07

Pazopanib Hydrochloride and Topotecan Hydrochloride in Treating Patients With Metastatic Soft Tissue and Bone Sarcomas

178 enrolled 16 charts

Liposarcoma, Sarcoma, Osteosarcoma

NCT01532687 2021-09-27

Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma

54 enrolled 12 charts

Chondrosarcoma, Extraskeletal Myxoid, Fibrosarcoma, Hemangiosarcoma, Leiomyosarcoma, Liposarcoma, Rhabdomyosarcoma, Sarcoma, Sarcoma, Synovial, Sarcoma, Alveolar Soft Part, Neurofibrosarcoma, Hemangioendothelioma, Epithelioid, Histiocytoma, Malignant Fibrous, Desmoplastic Small Round Cell Tumor

NCT01543802 2021-01-26

NOPASS

Phase 2 Terminated

21 enrolled

NCT03139331 2021-01-05

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

16 enrolled

NCT02300545 2020-08-05

Pazopanib as Front-Line Therapy in Patients With Non-Resectable or Metastatic Soft Tissue Sarcomas Who Are Not Candidates for Chemotherapy

56 enrolled 11 charts

NCT01446809 2020-04-13

Pazopanib Hydrochloride Followed by Chemotherapy and Surgery in Treating Patients With Soft Tissue Sarcoma

Phase NA Completed

23 enrolled 16 charts

NCT01593748 2020-04-06

A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma

90 enrolled 12 charts

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicSarcomaThoracic

NCT01392352 2020-02-13

HYPAZ

Phase 2 Terminated

31 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Gastrointestinal Neoplasms, Glioblastoma, Hypertension, Melanoma, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Small Cell Lung Carcinoma

NCT02795819 2019-10-24

Study of the Pan-DAC Inhibitor AR-42 and Pazopanib in Advanced Sarcoma and Kidney Cancer

Phase 1 Terminated

6 enrolled 12 charts

GenitourinarySarcoma

Carcinoma, Renal Cell, Neoplasm Metastasis, Sarcoma

NCT02575066 2019-06-27

PASART-2

Phase 2 Terminated

25 enrolled

NCT01438554 2018-08-29

Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma

GastrointestinalHead & NeckSarcoma

89 enrolled

Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma

NCT01418001 2018-01-11

Gemcitabine and Docetaxel in Combination With Pazopanib (Gem/Doce/Pzb) for the Neoadjuvant Treatment of Soft Tissue Sarcoma (STS)

Phase 1/2 Terminated

5 enrolled 6 charts

BreastGastrointestinalGenitourinaryHead & NeckSarcomaThoracic

Leiomyosarcoma, Sarcoma, Neurofibrosarcoma, Histiocytoma, Histiocytoma, Malignant Fibrous

NCT01012362 2017-12-28

Study of Pazopanib and Ixabepilone in Patients With Solid Tumors

Phase 1 Terminated

31 enrolled 12 charts

Breast Neoplasms, Colonic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT01995981 2017-12-19

PREDICT

Completed

22 enrolled

NCT03149120 2017-08-22

Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas

Phase 2 Withdrawn

Neoplasm Metastasis, Sarcoma

NCT01861951 2017-08-21

EPAZ

120 enrolled

NCT01719302 2016-06-16

Docetaxel, Gemcitabine and Pazopanib as Treatment for Soft Tissue Sarcoma

Phase 1/2 Completed

6 enrolled

NCT01985295 2015-10-09

PASART-1

12 enrolled